Creative Planning Acquires Shares of 17,023 Liquidia Co. (NASDAQ:LQDA)

Creative Planning acquired a new stake in Liquidia Co. (NASDAQ:LQDA) during the third quarter, HoldingsChannel reports. The firm acquired 17,023 shares of the company’s stock, valued at approximately $170,000.

A number of other institutional investors also recently bought and sold shares of LQDA. Quest Partners LLC purchased a new stake in Liquidia during the second quarter worth about $27,000. Hilltop National Bank purchased a new stake in Liquidia during the second quarter worth about $33,000. Whitcomb & Hess Inc. boosted its holdings in Liquidia by 10.2% during the third quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock worth $116,000 after buying an additional 1,074 shares in the last quarter. Deuterium Capital Management LLC purchased a new stake in Liquidia during the second quarter worth about $120,000. Finally, DMC Group LLC purchased a new stake in Liquidia during the second quarter worth about $122,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently commented on LQDA. Raymond James raised shares of Liquidia from an “outperform” rating to a “strong-buy” rating in a report on Monday, August 19th. Needham & Company LLC reaffirmed a “buy” rating and issued a $25.00 price target on shares of Liquidia in a report on Monday, August 19th. Scotiabank began coverage on shares of Liquidia in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price target on the stock. BTIG Research reduced their price target on shares of Liquidia from $29.00 to $25.00 and set a “buy” rating on the stock in a report on Monday, August 19th. Finally, HC Wainwright reduced their price target on shares of Liquidia from $32.00 to $29.00 and set a “buy” rating on the stock in a report on Tuesday, August 20th. One analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Liquidia currently has a consensus rating of “Moderate Buy” and an average price target of $24.67.

Liquidia Trading Down 2.7 %

Shares of NASDAQ LQDA opened at $10.73 on Tuesday. The stock has a fifty day moving average price of $10.40 and a 200 day moving average price of $11.55. The company has a market cap of $823.96 million, a P/E ratio of -6.83 and a beta of 0.21. Liquidia Co. has a 12-month low of $6.10 and a 12-month high of $16.99.

Insider Activity

In related news, Director Caligan Partners Lp purchased 150,000 shares of Liquidia stock in a transaction dated Friday, August 30th. The shares were acquired at an average price of $9.51 per share, with a total value of $1,426,500.00. Following the completion of the transaction, the director now owns 6,994,997 shares of the company’s stock, valued at approximately $66,522,421.47. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Liquidia news, insider Rajeev Saggar sold 2,260 shares of the firm’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $11.11, for a total value of $25,108.60. Following the transaction, the insider now owns 207,383 shares of the company’s stock, valued at $2,304,025.13. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Caligan Partners Lp bought 150,000 shares of the business’s stock in a transaction on Friday, August 30th. The stock was acquired at an average cost of $9.51 per share, for a total transaction of $1,426,500.00. Following the acquisition, the director now directly owns 6,994,997 shares of the company’s stock, valued at $66,522,421.47. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 21,551 shares of company stock worth $236,021 over the last ninety days. Corporate insiders own 30.10% of the company’s stock.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).